Immune response to COVID-19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics.
作者信息
Megna Matteo, Potestio Luca, Battista Teresa, Camela Elisa, Genco Lucia, Noto Matteo, Fabbrocini Gabriella, Martora Fabrizio
机构信息
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
出版信息
Clin Exp Dermatol. 2022 Dec;47(12):2310-2312. doi: 10.1111/ced.15395. Epub 2022 Sep 26.
Abstract
摘要
相似文献
1
Immune response to COVID-19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics.接受生物制剂治疗的银屑病患者对COVID-19 mRNA疫苗的免疫反应。
Clin Exp Dermatol. 2022 Dec;47(12):2310-2312. doi: 10.1111/ced.15395. Epub 2022 Sep 26.
2
Comment on 'Immune response to COVID-19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics'.关于“接受生物制剂治疗的银屑病患者对新冠病毒mRNA疫苗的免疫反应”的评论
Clin Exp Dermatol. 2024 Mar 21;49(4):394. doi: 10.1093/ced/llad392.
3
New-onset and flares of psoriasis after COVID-19 infection or vaccination successfully treated with biologics: a case series.新型冠状病毒感染或接种疫苗后新发及复发的银屑病经生物制剂成功治疗：病例系列
J Dermatolog Treat. 2023 Dec;34(1):2198050. doi: 10.1080/09546634.2023.2198050.
4
A survey of psoriasis patients on biologics during COVID-19: a single centre experience.COVID-19期间银屑病患者生物制剂使用情况的调查：单中心经验
J Dermatolog Treat. 2022 Feb;33(1):596. doi: 10.1080/09546634.2020.1770165. Epub 2020 May 25.
5
The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience.新型冠状病毒肺炎感染对接受生物制剂治疗的银屑病患者的影响：意大利的经验。
Clin Exp Dermatol. 2022 Dec;47(12):2280-2282. doi: 10.1111/ced.15336. Epub 2022 Sep 19.
6
Immunity 6 months after COVID-19 vaccination in patients with psoriasis treated with immunomodulatory drugs.接受免疫调节药物治疗的银屑病患者接种新冠疫苗6个月后的免疫情况。
Br J Dermatol. 2023 Apr 20;188(5):e38. doi: 10.1093/bjd/ljad094.
7
Understanding views of patients on biologics for psoriasis amid the COVID-19 pandemic.
J Eur Acad Dermatol Venereol. 2021 Apr;35(4):e249-e251. doi: 10.1111/jdv.17091. Epub 2020 Dec 29.
8
Safety of SARS-CoV-2 vaccines in psoriatic patients treated with biologics: A real life experience.生物制剂治疗的银屑病患者接种 SARS-CoV-2 疫苗的安全性：真实世界经验。
Dermatol Ther. 2022 Jan;35(1):e15177. doi: 10.1111/dth.15177. Epub 2021 Nov 15.
9
Clinical management of psoriasis patients during the COVID-19 pandemic.COVID-19 大流行期间银屑病患者的临床管理。
J Dermatolog Treat. 2022 Mar;33(2):1166-1167. doi: 10.1080/09546634.2020.1781045. Epub 2020 Jun 22.
10
A survey of psoriasis patients on biologics during COVID-19: a high-epidemic area experience - Franche Comté, France.新冠疫情期间法国弗朗什-孔泰大区银屑病生物制剂治疗患者的调查
Eur J Dermatol. 2021 Feb 1;31(1):101-103. doi: 10.1684/ejd.2020.3960.
引用本文的文献
1
The Impact of Psoriasis Treatments on the Risk of Skin Cancer: A Narrative Review.银屑病治疗对皮肤癌风险的影响：叙述性综述。
Adv Ther. 2024 Oct;41(10):3778-3791. doi: 10.1007/s12325-024-02968-w. Epub 2024 Aug 28.
2
Risk Factors for Psoriasis Flares: A Narrative Review.银屑病发作的危险因素：一篇叙述性综述。
Psoriasis (Auckl). 2024 May 30;14:39-50. doi: 10.2147/PTT.S323281. eCollection 2024.
3
Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study.替拉珠单抗在抗IL-17治疗失败的银屑病患者中的有效性和安全性：一项为期28周的真实世界研究。
Clin Cosmet Investig Dermatol. 2024 May 7;17:1037-1042. doi: 10.2147/CCID.S464326. eCollection 2024.
4
Management of Psoriasis Patients with Serious Infectious Diseases.严重感染性疾病银屑病患者的管理。
Adv Ther. 2024 Jun;41(6):2099-2111. doi: 10.1007/s12325-024-02873-2. Epub 2024 May 6.
5
Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines among Patients with Immune-Mediated Dermatological Diseases: A Systematic Review and Meta-analysis.免疫介导性皮肤病患者中 COVID-19 疫苗的免疫原性、有效性和安全性：一项系统评价与荟萃分析
Acta Derm Venereol. 2024 May 2;104:adv40009. doi: 10.2340/actadv.v104.40009.
6
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials.白细胞介素23/17轴在银屑病治疗中的作用：临床试验综述
Clin Cosmet Investig Dermatol. 2024 Apr 10;17:829-842. doi: 10.2147/CCID.S462797. eCollection 2024.
7
Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study.癌症患者银屑病的生物治疗：一项为期8年的回顾性真实世界研究。
J Clin Med. 2024 Mar 27;13(7):1940. doi: 10.3390/jcm13071940.
8
Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities.银屑病与分子靶向治疗：预防心血管合并症的疗效证据
Dermatol Ther (Heidelb). 2024 Apr;14(4):841-852. doi: 10.1007/s13555-024-01152-w. Epub 2024 Apr 9.
9
The Past, the Present and the Future of Teledermatology: A Narrative Review.远程皮肤病学的过去、现在与未来：一篇叙述性综述
Clin Cosmet Investig Dermatol. 2024 Mar 21;17:717-723. doi: 10.2147/CCID.S462799. eCollection 2024.
10
Psoriasis and biological drugs at the time of SARS-CoV-2 infection: a mini review outlining risk of infection, seroprevalence, and safety and efficacy of the BNT162b2 vaccine.COVID-19 感染时的银屑病和生物药物：概述感染风险、血清流行率以及 BNT162b2 疫苗安全性和有效性的小型综述。
Front Immunol. 2024 Jan 30;15:1354729. doi: 10.3389/fimmu.2024.1354729. eCollection 2024.
Zotero 插件